Antipodes Partners LTD Novo Cure LTD Transaction History
Antipodes Partners LTD
- $3 Billion
- Q2 2025
A detailed history of Antipodes Partners LTD transactions in Novo Cure LTD stock. As of the latest transaction made, Antipodes Partners LTD holds 1,119 shares of NVCR stock, worth $12,879. This represents 0.0% of its overall portfolio holdings.
Number of Shares
1,119Holding current value
$12,879% of portfolio
0.0%Shares
1 transactions
Others Institutions Holding NVCR
# of Institutions
265Shares Held
79.2MCall Options Held
970KPut Options Held
118K-
Black Rock Inc. New York, NY12.1MShares$140 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA11.3MShares$130 Million0.0% of portfolio
-
Capital International Investors Los Angeles, CA8.95MShares$103 Million0.03% of portfolio
-
Soleus Capital Management, L.P. Greenwich, CT5.52MShares$63.6 Million8.14% of portfolio
-
Capital World Investors Los Angeles, CA5.22MShares$60 Million0.02% of portfolio
About NovoCure Ltd
- Ticker NVCR
- Exchange NASDAQ
- Sector Healthcare
- Industry Medical Instruments & Supplies
- Shares Outstandng 104,950,000
- Market Cap $1.21B
- Description
- NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Europe, the Middle East, Africa, Japan, and Greater China. Its TTFields devices include Optune for the treatment of glioblastoma; and Optu...